{
    "nct_id": "NCT03031691",
    "official_title": "A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if KRAS wild-type, an anti-EGFR therapy\n* ECOG performance status 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors\n* Subjects with known active HIV infection. Subjects with HIV that are under a stable anti-retroviral regimen and have no evidence of immune deficiency (normal CD4 counts), undetectable viral load, and no HIV-related infections are eligible\n* Subjects with uncontrolled diarrhea <30 days prior to first administration of study drug\n* Subjects with any history of or current clinically significant gastrointestinal disease including, but not limited to:\n\n  * Inflammatory bowel disease (including ulcerative colitis and Crohn's disease)\n  * Active peptic ulcer disease\n  * Known intraluminal metastatic lesion(s) with risk of bleeding",
    "miscellaneous_criteria": ""
}